These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 23263548)

  • 1. The effects of fenofibrate on inflammation and cardiovascular markers in patients with active rheumatoid arthritis: a pilot study.
    Shirinsky I; Polovnikova O; Kalinovskaya N; Shirinsky V
    Rheumatol Int; 2013 Dec; 33(12):3045-8. PubMed ID: 23263548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis.
    Okamoto H; Iwamoto T; Kotake S; Momohara S; Yamanaka H; Kamatani N
    Clin Exp Rheumatol; 2005; 23(3):323-30. PubMed ID: 15971419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of erosive osteoarthritis with peroxisome proliferator-activated receptor alpha agonist fenofibrate: a pilot study.
    Shirinsky IV; Shirinsky VS
    Rheumatol Int; 2014 May; 34(5):613-6. PubMed ID: 23620259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Niclosamide as an adjuvant to etanercept in treatment patients with active rheumatoid arthritis: an 8-week randomized controlled pilot study.
    Al-Gareeb AIA; Gorial FI; Mahmood AS
    Clin Rheumatol; 2018 Oct; 37(10):2633-2641. PubMed ID: 29882203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis.
    Goto M
    Mod Rheumatol; 2010 Jun; 20(3):238-43. PubMed ID: 20143119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance.
    Okopień B; Krysiak R; Herman ZS
    J Clin Endocrinol Metab; 2006 May; 91(5):1770-8. PubMed ID: 16492702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The peroxisome proliferator activated receptor-γ pioglitazone improves vascular function and decreases disease activity in patients with rheumatoid arthritis.
    Marder W; Khalatbari S; Myles JD; Hench R; Lustig S; Yalavarthi S; Parameswaran A; Brook RD; Kaplan MJ
    J Am Heart Assoc; 2013 Nov; 2(6):e000441. PubMed ID: 24252844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice.
    Lalloyer F; Wouters K; Baron M; Caron S; Vallez E; Vanhoutte J; Baugé E; Shiri-Sverdlov R; Hofker M; Staels B; Tailleux A
    Arterioscler Thromb Vasc Biol; 2011 Jul; 31(7):1573-9. PubMed ID: 21474829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose.
    Buldak L; Dulawa-Buldak A; Labuzek K; Okopien B
    Int J Clin Pharmacol Ther; 2012 Nov; 50(11):805-13. PubMed ID: 22943927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of fenofibrate on lipid profile, endothelial dysfunction, and inflammatory markers in type 2 diabetes mellitus patients with typical and mixed dyslipidemia.
    Ghani RA; Bin Yaakob I; Wahab NA; Zainudin S; Mustafa N; Sukor N; Wan Mohamud WN; Kadir KA; Kamaruddin NA
    J Clin Lipidol; 2013; 7(5):446-53. PubMed ID: 24079286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy.
    Grisar J; Aletaha D; Steiner CW; Kapral T; Steiner S; Säemann M; Schwarzinger I; Buranyi B; Steiner G; Smolen JS
    Ann Rheum Dis; 2007 Oct; 66(10):1284-8. PubMed ID: 17293363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of rheumatoid arthritis following adjunct statin therapy.
    Das S; Mohanty M; Padhan P
    Indian J Pharmacol; 2015; 47(6):605-9. PubMed ID: 26729950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effects of fenofibrate and resveratrol in an aggressive model of rheumatoid arthritis in rats.
    Wahba MG; Messiha BA; Abo-Saif AA
    Pharm Biol; 2016 Sep; 54(9):1705-15. PubMed ID: 26704826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFα.
    Castro-Villegas C; Pérez-Sánchez C; Escudero A; Filipescu I; Verdu M; Ruiz-Limón P; Aguirre MA; Jiménez-Gomez Y; Font P; Rodriguez-Ariza A; Peinado JR; Collantes-Estévez E; González-Conejero R; Martinez C; Barbarroja N; López-Pedrera C
    Arthritis Res Ther; 2015 Mar; 17(1):49. PubMed ID: 25860297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
    Genovese MC; Kalunian K; Gottenberg JE; Mozaffarian N; Bartok B; Matzkies F; Gao J; Guo Y; Tasset C; Sundy JS; de Vlam K; Walker D; Takeuchi T
    JAMA; 2019 Jul; 322(4):315-325. PubMed ID: 31334793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of lipid phenotypes, serum lipid behaviour over follow-up and predictors of serum lipid levels in a cohort of Mexican Mestizo early rheumatoid arthritis patients treated with conventional disease-modifying anti-rheumatic drugs.
    Sánchez T; Contreras-Yáñez I; Elías-López D; Aguilar Salinas CA; Pascual-Ramos V
    Clin Exp Rheumatol; 2014; 32(4):509-15. PubMed ID: 25005131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome.
    Belfort R; Berria R; Cornell J; Cusi K
    J Clin Endocrinol Metab; 2010 Feb; 95(2):829-36. PubMed ID: 20061429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation among anti-rheumatic drug therapy, CD14(+)CD16(+) blood monocytes and disease activity markers (DAS28 and US7 scores) in rheumatoid arthritis: A pilot study.
    Amoruso A; Sola D; Rossi L; Obeng JA; Fresu LG; Sainaghi PP; Pirisi M; Brunelleschi S
    Pharmacol Res; 2016 May; 107():308-314. PubMed ID: 27045818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential of circulating microRNA-125a and microRNA-125b as markers for inflammation and clinical response to infliximab in rheumatoid arthritis patients.
    Cheng P; Wang J
    J Clin Lab Anal; 2020 Aug; 34(8):e23329. PubMed ID: 32281166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.